Jump to navigation Jump to search
Clinical data
ATC code
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass170.17 g/mol

WikiDoc Resources for Linsidomine


Most recent articles on Linsidomine

Most cited articles on Linsidomine

Review articles on Linsidomine

Articles on Linsidomine in N Eng J Med, Lancet, BMJ


Powerpoint slides on Linsidomine

Images of Linsidomine

Photos of Linsidomine

Podcasts & MP3s on Linsidomine

Videos on Linsidomine

Evidence Based Medicine

Cochrane Collaboration on Linsidomine

Bandolier on Linsidomine

TRIP on Linsidomine

Clinical Trials

Ongoing Trials on Linsidomine at Clinical

Trial results on Linsidomine

Clinical Trials on Linsidomine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Linsidomine

NICE Guidance on Linsidomine


FDA on Linsidomine

CDC on Linsidomine


Books on Linsidomine


Linsidomine in the news

Be alerted to news on Linsidomine

News trends on Linsidomine


Blogs on Linsidomine


Definitions of Linsidomine

Patient Resources / Community

Patient resources on Linsidomine

Discussion groups on Linsidomine

Patient Handouts on Linsidomine

Directions to Hospitals Treating Linsidomine

Risk calculators and risk factors for Linsidomine

Healthcare Provider Resources

Symptoms of Linsidomine

Causes & Risk Factors for Linsidomine

Diagnostic studies for Linsidomine

Treatment of Linsidomine

Continuing Medical Education (CME)

CME Programs on Linsidomine


Linsidomine en Espanol

Linsidomine en Francais


Linsidomine in the Marketplace

Patents on Linsidomine

Experimental / Informatics

List of terms related to Linsidomine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Linsidomine (3-morpholinosydnonimine or SIN-1[1]) is a vasodilator. It is a metabolite of the antianginal drug molsidomine and acts by releasing NO from the endothelial cells nonenzymatically. It also hyperpolarizes the cell membrane through influencing the sodium-potassium pump and thereby rendering it less responsive to adrenergic stimulation. Linsidomine injection at a dose of 1 mg produces usable erection in about 70% of patients and full erection in up to 50% of patients. Linsidomine does not appear to be associated with priapism.

Linsidomine is neurotoxic and promotes oxidative stress on neurons.[2] Linsidomine is a peroxynitrite-generating compound involved in the pathogenesis of neurodegenerative diseases.[3]


  1. Wen, TC.; Rogido, MR.; Moore, JE.; Genetta, T.; Peng, H.; Sola, A. (Oct 2005). "Cardiotrophin-1 protects cortical neuronal cells against free radical-induced injuries in vitro". Neurosci Lett. 387 (1): 38–42. doi:10.1016/j.neulet.2005.07.018. PMID 16084018.
  2. Wallace, DR.; Dodson, S.; Nath, A.; Booze, RM. (Jan 2006). "Estrogen attenuates gp120- and tat1-72-induced oxidative stress and prevents loss of dopamine transporter function". Synapse. 59 (1): 51–60. doi:10.1002/syn.20214. PMID 16237680.
  3. Jang, JH.; Aruoma, OI.; Jen, LS.; Chung, HY.; Surh, YJ. (Feb 2004). "Ergothioneine rescues PC12 cells from beta-amyloid-induced apoptotic death". Free Radic Biol Med. 36 (3): 288–99. doi:10.1016/j.freeradbiomed.2003.11.005. PMID 15036348.